Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
ACET Stock — Adicet Bio Inc
Adicet Bio Inc (ACET)
Updated October 16, 2026.
ACET is a Stock. Total return is -99.8% over the past 8.7 years, 303.9 points behind SPY at 204.1%.
Adicet Bio is a clinical stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, with lead candidate prulacabtagene leucel targeting CD20 for autoimmune conditions and ADI-212 in development for prostate cancer. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotechnology development, though it carries the risks associated with clinical stage companies without approved products.
ACET dividend yield and income
Price as of 2026-10-16.
The ex-dividend date is 09/21/2018. The payment date is 10/09/2018.
| Ex-date | As paid | Per current share | Change from previous payment |
|---|---|---|---|
| 2018-09-21 | $0.00009 | $0.01008 | 0.0% Unclassified cash |
| 2018-06-07 | $0.00009 | $0.01008 | -84.5% Unclassified cash |
| 2018-03-08 | $0.00058 | $0.06496 | — |
| 2018 total | — | $0.08512 | — |
ACET performance versus SPY
Price and return data through 2026-10-16.
Total return is -99.8% over the past 8.7 years, 303.9 points behind SPY at 204.1%. Over the past year its total return — price change plus distributions reinvested — is -72.5%. Its deepest 1-year drawdown was 72.5%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -49.5% | — |
| 3M | -44.4% | — |
| 6M | -43.2% | — |
| YTD | -45.7% | — |
| 1Y | -72.5% | — |
| 2Y CAGR | — | -56.20% |
| 3Y CAGR | — | -41.50% |
| 5Y CAGR | — | -48.70% |
| Since inception (8.7 years) | -99.8% | -49.90% |
ACET key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 01/26/2018
- Distribution frequency
- None
- Last close
- $4.57 (as of 2026-10-16)
- Market cap
- $42,782,009
- Average volume
- 188437.0
- Ex-dividend date
- 09/21/2018
- Payment date
- 10/09/2018
- Beta
- 1.627
- Payout ratio
- 0.0%
- EPS
- $-10.42
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
ACET risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 72.5%.
Who may consider ACET — and who may not
It is a weaker fit for investors who need monthly cash flow (ACET does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on ACET
Frequently asked questions
Does ACET pay monthly?
No. ACET does not currently distribute.
When does ACET pay a dividend?
ACET does not currently distribute. The ex-dividend date is 09/21/2018. The payment date is 10/09/2018.
How has ACET performed?
Total return is -99.8% over the past 8.7 years, 303.9 points behind SPY at 204.1%. Over the past year its total return — price change plus distributions reinvested — is -72.5%. Its deepest 1-year drawdown was 72.5%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.